参松养心胶囊在老年急性心肌梗死患者中的应用优势

目的:探讨参松养心胶囊在老年急性心肌梗死患者中的应用优势。方法:选取2018年2月至2019年1月收治的108例老年急性心肌梗死患者按随机数字表法分成观察组和对照组,每组各54例。对照组按常规方式治疗,观察组在常规方式治疗的基础上使用参松养心胶囊。对比两组临床疗效、不良反应及治疗前、后炎症因子水平和心功能。结果:观察组治疗总有效率为96.30%,对照组治疗总有效率83.33%,两组差异有统计学意义(χ²=4.96,P<0.05);治疗前两组CRP,IL-6,TNF-α差异无统计学意义(P>0.05),治疗后差异均有统计学意义(均P<0.05)。观察组治疗前左室舒张末期内径(left ventricular end diastolic diameter,LVEDD)、左室收缩末期内径(left ventricular end-systolic dimension,LVESD)、左室射血分数(left ventricular ejection fraction,LVEF)差异无统计学意义(P>0.05),治疗后差异有统计学意义(均P<0.05);观察组不良反应发生率7.14%,对照组不良反应发生率5.56%,两组差异无统计学意义(χ²=0.15,P>0.05)。结论:参松养心胶囊能有效提高老年急性心肌梗死患者的临床疗效,并改善炎症因子水平及心功能指标,且无明显不良反应,是有效而安全的治疗方式。

Application advantages of Shensong Yangxin capsule in elderly patients with acute myocardial infarction

Objective:To explore the advantages of Shensong Yangxin capsule in elderly patients with acute myocardial infarction.Methods:From February 2018 to January 2019,108 elderly patients with acute myocardial infarction were divided into observation group and control group,according to the method of random number table.The control group was treated by routine method,and the observation group used Shensong Yangxin capsule on the basis of routine treatment.The clinical efficacy,adverse reactions,levels of inflammatory factors before and after treatment and cardiac function were compared between the two groups.Results:The total effective rate of treatment in the observation group was 96.30%,and that in control group was 83.33%;the difference between the two groups was statistically significant(χ²=4.96,P<0.05).There was no statistical difference in CRP,IL-6,TNF-αbefore the treatment between the two groups(P>0.05);and after the treatment there were significant differences in the above indexes between the two groups(all P<0.05).There was no significant difference in left ventricular end diastolic diameter(LVEDD),left ventricular end-systolic dimension(LVESD),left ventricular ejection fraction(LVEF)before the treatment between the two groups(P>0.05);there were significant differences in the above indexes between the two groups after the treatment(all P<0.05).The incidence of adverse reactions in the observation group was 7.14%,and the incidence of adverse reactions in the control group was 5.56%;there was no significant difference between the two groups(χ²=0.15,P>0.05).Conclusion:Shensong Yangxin capsule can effectively improve the clinical efficacy of elderly patients with acute myocardial infarction,improve the level in inflammatory factors and cardiac function indicators,without obvious adverse reactions.It is an effective and safe method for treatment.